drugset
drugset / Trial / NCT03354728

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728 ↗

Phase 1/2 Recruiting 80 enrolled City of Hope Medical Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care

Summary

This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.

Timeline

Start
2018-05-11
Primary completion
2026-12-11
Completion
2026-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Vaccine — Intramuscular

Indications

cytomegalovirus infection disease related to hematopoietic stem cell transplant